Search results
Showing 436 to 450 of 478 results for cost benefit of cancer drugs
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.
Recommendation ID NG145/5 Question What is the clinical and cost effectiveness of dosimetry-guided radioactive iodine strategies for...
Recommendation ID NG145/4 Question What is the long-term clinical and cost effectiveness, including safety, of radioactive iodine for...
with Graves' disease who have a particularly good response to antithyroid drugs? Any explanatory notes(if applicable) Why the committee...
Suspected sepsis in people aged 16 or over: recognition, assessment and early management (NG253)
This guideline covers the recognition, diagnosis and early management of suspected sepsis in people aged 16 or over who are not and have not recently been pregnant. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)
This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.
This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual
NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of
Evidence-based recommendations on idebenone (Raxone) for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over.
Show all sections
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .